查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627872

IgA腎臟病治療的全球市場：預測（2025-2030 年）

IGA Nephropathy Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球IGA腎臟病疾病治療市場規模預計將從2025年的315,914,000美元成長到2030年的591,844,000美元，複合年成長率為13.38%。

由於腎臟疾病盛行率不斷增加，預計未來幾年對 IGA腎臟病變治療的需求將會增加。正在進行研究以開發新的有效治療方法，預計將在預測期內繼續為市場相關人員提供成長機會。

此外，新藥的批准和核准、提高人們對 IgA腎臟病認知的大規模宣傳活動以及健康檢查可能會對市場成長產生積極影響。例如，2022年9月，美國食品藥物管理局核准了Eldon Pharmaceutical的臨床實驗新藥（IND）申請，用於評估tegopulvert治療IgA腎臟病的效果。

此外，Cariditas 將於 2022 年 5 月啟動 IgA腎臟病教育計劃“IgAN Connect”，為剛剛診斷出 IgA腎臟病的人和患有 IgA腎臟病多年的人提供必要的工具和資訊來源。這些藥物的核准和許可，加上 IgA腎臟病的教育計劃，預計將為未來幾年的 IgA腎臟病市場提供積極的前景。

IGA腎臟病治療市場的促進因素

  • 慢性腎臟病盛行率的上升將推動全球市場的成長

慢性腎臟病的增加增加了對 IgA腎臟病治療的需求並推動市場成長。新型致病機制的開發和強大的創新療法管線預計將在 IgA腎臟病市場的成長中發揮關鍵作用。

此外，久坐的生活方式、過度吸煙、飲酒量增加以及肥胖的增加都會導致這種疾病的發病率增加。例如，根據美國疾病管制與預防中心2023年發布的報告，美國慢性腎臟病患者的年齡範圍為18歲至44歲之間的總人口的6.30％，以及20歲至44歲之間的12.30％。歲和64腎臟病之間。

IGA腎臟病治療市場的地域展望

  • 預計北美在預測期內將繼續佔據顯著的市場佔有率

從地區來看，IGA腎臟病疾病治療市場分為北美、南美、歐洲、中東和非洲以及亞太地區。

在預測期內，由於主要區域經濟體慢性病盛行率不斷上升，北美地區預計將以恆定速度成長，並可能佔據重要的市場佔有率。根據美國衛生與公共服務部國家糖尿病、消化和腎臟疾病研究所的數據，超過七分之一的美國成年人患有慢性腎臟病(CKD)。

根據美國疾病管制與預防中心的數據，近 14% 的美國人（即 3,550 萬人）患有慢性腎臟病。此外，根據同一資訊來源，女性比男性更容易患慢性腎臟病。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中釋放新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業和市場考量、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022年至2030年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 區域收益成長和預測分析，包括細分市場和國家
  • 公司簡介（主要是策略、產品、財務資訊、主要動態等）

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章 IGA腎臟病疾病治療市場：通過測試

  • 介紹
  • 驗血
  • 尿液檢查
  • 腎臟測試
  • 碘丘氨酸清除率試驗
  • 其他

第6章 IGA腎臟病疾病治療市場：依治療類型

  • 介紹
  • 皮質類固醇
  • 免疫抑制藥物
  • ACE抑制劑和白蛋白
  • 改善飲食習慣
  • 治療

第7章 IGA腎臟病治療市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 併購/協議/合作
  • 競爭對手儀表板

第9章 公司簡介

  • TRAVERE THERAPEUTICS INC.
  • CALLIDITAS THERAPEUTICS AB
  • Omeros
  • NOVARTIS PHARMACEUTICALS
  • CHINOOK THERAPEUTICS INC
  • VERA THERAPEUTICS, INC
  • Merck KGAA
  • REATA PHARMACEUTICALS INC.
  • IONIS PHARMACEUTICALS
  • Stada Group
簡介目錄
Product Code: KSI061612300

The IGA nephropathy disease treatment market is projected to grow from US$315.914 million in 2025 to US$591.844 million in 2030 at a CAGR of 13.38%.

The need for IgA nephropathy disease treatment is estimated to grow over the coming years on account of the increasing prevalence of kidney diseases. Research is being conducted to develop new and effective treatment methods and continue to offer growth opportunities for the market players during the forecast period.

Moreover, clearances and approval of new drugs as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups will have a positive impact on the market growth. For instance, the US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.

Additionally, in May 2022, Calliditas launched its educational program on IgA Nephropathy called "IgAN Connect" which will provide necessary tools and sources to people who have either recently been diagnosed with IgA Nephropathy or are living for many years. Such drug approval and clearances coupled with education programs relating to IgA Nephropathy present a positive outlook for the IgA Nephropathy market over the coming years

IGA nephropathy disease treatment market drivers

  • Growing prevalence of chronic kidney disease is driving the market growth globally.

The incidences of chronic kidney diseases are increasing the demand for IgA nephropathy which is boosting the market growth. The development of new pathogenic mechanisms and a strong pipeline of innovative prospective therapeutics are anticipated to both play a significant role in the growth of the IgA Nephropathy market.

In addition, sedentary lifestyles, excessive smoking, increased alcohol consumption, and an increase in obesity all contribute to the disease's rising occurrence. For instance, as per the report of Center for Disease Control and Prevention, published in 2023, the people suffering from CKD in the United States with an age range between 18 to 44 was 6.30% of the overall population of that age range, for people aged between 45-64 was 12.30% and that for 65+ people it was 33.70%, hence the IgA nephropathy disease treatment market is anticipated to experience considerable expansion throughout the projected period.

IGA nephropathy disease treatment market geographical outlook

  • North America will continue to hold a remarkable share of the market during the forecast period.

Geographically, the IGA nephropathy disease treatment market has been segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific.

During the forecast period, the North American region is expected to grow at a constant rate and will constitute a considerable market share fueled by the growing chronic disease prevalence in major regional economies. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults.

And according to the Center For Disease Control and Prevention, nearly 14% of the country's total population or 35.5 million Americans suffer from chronic kidney disease. Moreover, the same source also specified that by gender, women are more prone to be affected by chronic kidney disease as compared to men.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The IGA Nephropathy Disease Treatment Market is analyzed into the following segments:

By Test

  • Blood Test
  • Urine Test
  • Kidney Test
  • Iothalamate Clearence Test
  • Others

By Treatment Type

  • Corticosteroids
  • Immunosuppressive Drugs
  • Ace Inhibitors and Arbs
  • Diet Change
  • Therapy

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TEST

  • 5.1. Introduction
  • 5.2. Blood Test
  • 5.3. Urine Test
  • 5.4. Kidney Test
  • 5.5. Iothalamate Clearance Test
  • 5.6. Others

6. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Immunosuppressive Drugs
  • 6.4. Ace Inhibitors and Arbs
  • 6.5. Diet Change
  • 6.6. Therapy

7. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. TRAVERE THERAPEUTICS INC.
  • 9.2. CALLIDITAS THERAPEUTICS AB
  • 9.3. Omeros
  • 9.4. NOVARTIS PHARMACEUTICALS
  • 9.5. CHINOOK THERAPEUTICS INC
  • 9.6. VERA THERAPEUTICS, INC
  • 9.7. Merck KGAA
  • 9.8. REATA PHARMACEUTICALS INC.
  • 9.9. IONIS PHARMACEUTICALS
  • 9.10. Stada Group